Skip to main content
Premium Trial:

Request an Annual Quote

Arthur Riggs Dies

Arthur Riggs, one of the developers of recombinant DNA technology, has died, the Washington Post reports. He was 82.

Riggs, who spent 50 years at the City of Hope, worked with Keiichi Itakura, also from City of Hope, and Herbert Boyer, a founder of Genentech, to develop a synthetic gene encoding the hormone somatostatin but found that it was not stable unless combined with a larger protein, the Post writes. It adds that, according to Itakura, that combination was "a critical development." The trio then applied their approach to the more complex hormone insulin.

"We chose insulin because it looked doable, and there was a need," Riggs once said, according to the Post. "At the time, diabetics were being treated with cow insulin because there was no source of human insulin. And cow insulin resulted in a high rate of allergic reactions."

Their recombinant DNA approach is also the foundational basis for monoclonal antibodies, which are used to treat a range of conditions from cancer to COVID-19, the Post adds.

"You cannot overestimate the importance of this seminal work, not simply to people with diabetes, but also in helping to found the field of biotechnology," Peter Dervan from Caltech, where Riggs received his PhD, says in a statement.

Filed under

The Scan

Polygenic Risk Score to Predict Preeclampsia, Gestational Hypertension in Pregnant Women

Researchers in Nature Medicine provide new mechanistic insights into the development of hypertensive disorders of pregnancy, which may help develop therapeutics.

New Oral Nanomedicine Strategy Targets Gut-Brain Axis to Treat IBD

A new paper in Science Advances describes a platform to design polyphenol-armored oral medicines that are effective at treating inflammatory bowel disease.

Phylogenetic Data Enables New Floristic Map

Researchers in Nature Communications use angiosperm phylogenetic data to refine the floristic regions of the world.

Machine Learning Helps ID Molecular Mechanisms of Pancreatic Islet Beta Cell Subtypes in Type 2 Diabetes

The approach helps overcome limitations of previous studies that had investigated the molecular mechanisms of pancreatic islet beta cells, the authors write in their Nature Genetics paper.